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Summary at a Glance  
 
We investigated the associations between vitamin D status, the antimicrobial peptides 
cathelicidin and beta defensin-2 and outcomes in community acquired pneumonia. In 
hospitalised patients with community acquired pneumonia, vitamin D deficiency but 
not antimicrobial peptide levels were associated with increased 30-day mortality. 
Vitamin D was not associated with levels of the antimicrobial peptide cathelicidin or 
beta defensin-2.   
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Abstract  
 
Background and objective 
Vitamin D regulates the production of the antimicrobial peptides cathelicidin and beta 
defensin-2, which play an important role in the innate immune response to infection. 
We hypothesised that vitamin D deficiency would be associated with lower levels of 
these peptides and worse outcomes in patients admitted to hospital with community 
acquired pneumonia. 
 
Methods 
Associations between mortality and serum levels of 25-hydroxyvitamin D, 
cathelicidin, and beta defensin-2 were investigated in a prospective cohort of 112 
patients admitted with community acquired pneumonia during winter.  
 
Results 
Severe 25-hydroxyvitamin D deficiency (<30nmol/L) was common in this population 
(15%) and was associated with a higher 30-day mortality compared to patients with 
sufficient 25-hydroxyvitamin D(>50nmol/L) (OR 12.7, 95%CI 2.2-73.3, p=0.004). 
These associations were not explained by differences in age, co-morbidities, or the 
severity of the acute illness. Neither cathelicidin nor beta defensin-2 levels predicted 
mortality, although there was a trend towards increased mortality with lower 
cathelicidin (p=0.09). Neither cathelicidin nor beta defensin-2 levels correlated with 
25-hydroxyvitamin D.  
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Conclusions 
25-hydroxyvitamin D deficiency is associated with increased mortality in patients 
admitted to hospital with community acquired pneumonia during winter. Contrary to 
our hypothesis, 25-hydroxyvitamin D levels were not associated with levels of 
cathelicidin or beta defensin-2. 
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Introduction  
 
Vitamin D has long been known to have bactericidal, bacteriostatic and bacteriolytic 
properties in vivo and in vitro.1 More recently, associations between low serum 25-
hydroxyvitamin D levels and frequency of respiratory tract infections have been 
demonstrated in Finnish and American populations.2, 3  
 
Classically thought to be primarily responsible for calcium and bone homeostasis, 
vitamin D is now known to regulate the transcription of more than 900 target genes.4, 5  
Vitamin D response elements are present in promoter regions of the genes encoding 
for the antimicrobial peptides cathelicidin and beta defensin-2, suggesting that 
vitamin D plays a role in regulating their expression.6 Antimicrobial peptides are 
endogenously synthesized molecules found on mucosal and epithelial surfaces of all 
multicellular organisms. These molecules act as the first line of defence against 
bacterial and viral infections, in addition to having many other immunomodulatory 
functions. The 2 major families of antimicrobial peptides are the defensins, of which 
there are 6 alpha and 2 beta subclasses, and cathelicidins, of which only 1 subtype 
exists in humans, the human cathelicidin antimicrobial peptide hCAP18.7  
 
Antimicrobial peptide production by epithelial cells and leukocytes is initiated by 
binding of pathogen-associated molecular patterns to a subclass of pattern recognition 
receptors embedded in the plasma membranes of phagocytic cells, also known as 
Toll-like receptors.8 Toll-like receptor activation in human macrophages is associated 
with up-regulation of the vitamin D receptor and the CYP27B1 enzyme, which acts 
  
 
8
locally to hydrolyse the circulating form of vitamin D, 25-hydroxyvitamin D to 1,25-
dihydroxyvitamin D, its physiologically active form. Binding of 1,25-
dihydroxyvitamin D to the vitamin D receptor  leads to increased production of the 
antimicrobial peptides cathelicidin and defensin beta-2.6, 9, 10 In vitro studies have 
shown that low 25-hydroxyvitamin D levels are associated with reduced production of 
cathelicidin by stimulated human macrophages in response to toll-like receptor 
activation with Mycobacterium tuberculosis and that supplementation with 25-
hydroxyvitamin D restores cathelicidin production.10  
 
Sunlight exposure is the primary source of Vitamin D for most people.11 Hence 
vitamin D deficiency is common during the winter months in temperate regions 
including New Zealand.12 It is plausible that this contributes to the increased 
prevalence of respiratory infections such as pneumonia during winter.13 In a series of 
small studies of patients admitted with pneumonia, serum defensin levels were 2-3 
times higher than healthy controls, and normalised after completion of antibiotics.14, 15  
Smoking has been associated with reduced levels of beta defensin-2 in sputum and 
pharyngeal washings in acute pneumonia.16 There is otherwise a paucity of data about 
vitamin D and antimicrobial peptide levels during respiratory infections and how they 
contribute to the severity and outcome of these conditions. 
 
We prospectively studied the relationship between serum 25-hydroxyvitamin D and 
antimicrobial peptide levels in the setting of community acquired during the New 
Zealand winter. We hypothesized that vitamin D levels would influence the severity 
  
 
9
and outcomes of these conditions and that this would be mediated through differences 
in the levels of the antimicrobial peptides cathelicidin and beta defensin-2. 
 
Methods  
 
This was a prospective, descriptive study undertaken during the winter months of July 
to October, 2008, at the only acute-care hospital in Hamilton, New Zealand. All adult 
patients with community acquired pneumonia in this hospital are admitted to the 
Respiratory Medicine service. These patients were invited to participate in the study. 
All patients provided written informed consent. The study was approved by the 
Northern Y Regional Ethics Committee, New Zealand. (Ref NTY/08/05/045) 
 
Community acquired pneumonia was diagnosed by admitting physicians according to 
British Thoracic Society definitions.17 Clinical management followed local standards 
of practice and was not altered by participation in the study. Baseline demographic 
information including age, ethnicity, sex, smoking history and domicile status was 
recorded. The Charlson Index score, a validated marker of the burden of co-morbid 
illnesses,18, 19 and CURB65 score, a prognostic marker for patients admitted with 
pneumonia were also recorded.20   
 
Blood samples were collected within 24 hours of admission. These were analysed for 
serum 25-hydroxyvitamin D levels and C Reactive Protein (CRP). Serum was stored 
at -70C, and transferred to a separate laboratory for cathelicidin and beta defensin-2 
analysis. Patients taking vitamin D supplements were included, but not if they were 
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taking calcitriol (1,25-vitamin D3), which is not measured by the 25-hydroxyvitamin 
D assay used and likely to influence vitamin D status. 
 
In a convenience sample of 41 patients who attended out-patient clinic follow-up, 
typically 6 weeks after discharge, a second blood sample was obtained and analysed 
for serum cathelicidin. 
 
Serum 25-hydroxyvitamin D levels were measured using a competitive electro 
chemiluminescence assay kit (Elecsys, Roche Diagnostics, UK) and quantitative 
analysis of antimicrobial peptides in serum, was measured using the Human BD-2 
ELISA Development Kit (PeproTech Inc, 900-K172, USA) and Human LL-37 
ELISA Test Kit (Hycult Biotechnology, HK321, The Netherlands) according to 
manufacturer instructions. All ELISA assays were performed in duplicate and 
included internal standards used to construct standard curves for analyte concentration 
assessment.  
 
Our sample size was constrained by the number of patients admitted with pneumonia 
during the study period. However, based on previous reports12 we anticipated that 
35% of patients would have severe vitamin D deficiency (<30nmol/L) during the 
winter months. Predicting that there would be at least 100 admissions over the study 
period this provided 80% power to detect a difference in 30 day mortality of 5% and 
25% with sufficient and severe vitamin D deficiency respectively with a two sided 
alpha of 0.05. These mortality rates are similar to those found with low (0-1) and high 
(3-5) CURB65 scores.  
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Serum 25-hydroxyvitamin D, cathelicidin, and beta defensin-2 had skewed 
distributions and associations between the levels of these were assessed using 
Spearman’s (non-parametric) correlations. Levels of 25-hydroxyvitamin D were 
categorised as severely deficient (<30nmol/L), deficient (30-49nmol/L), and sufficient 
(≥50nmol/L) according to previously published cut points.11 Cathelicidin and beta 
defensin-2 levels were categorised by tertiles. The levels were also log-transformed to 
approximate normal distributions for further analyses.   
 
The primary outcome measure for this analysis was 30 day mortality. Associations 
between mortality and 25-hydroxyvitamin D levels used stepwise logistic regression 
to adjust for potential confounding variables including age, sex, diagnosis (pneumonia 
or COPD), co-morbidities using the Charlson Index, the severity of the acute illness 
using the CURB65 score, and the systemic inflammatory response measured by CRP. 
The analysis started with 25-hydroxyvitamin D as a predictor of mortality and 
additional variables were entered to the model if they were associated with mortality 
at p<0.05. The analysis was also run as a backward stepwise logistic regression 
starting with all the variables and removing those not significant at p<0.05. These 
analyses were repeated for cathelicidin, and beta defensin-2. Statistical analyses were 
done using STATA 10 (Stata Corporation, College Station, Texas 
 
Results 
128 eligible patients were assessed during the study period and 112 patients were 
included (Figure 1). A scatter plot of serum 25-hydroxyvitamin D, cathelicidin and 
beta defensin-2 levels are shown in Figure 2. 25-hydroxyvitamin D levels were 
  
 
12
available for all included patients. After routine tests were done, 12 and 9 patients had 
insufficient serum for beta defensin-2 and cathelicidin analyses respectively. 
 
Characteristics of the study population are shown in table 1. The 18 patients who were 
taking vitamin D supplements had higher 25-hydroxyvitamin D levels than those who 
were not (median values 85 nmol/L and 51 nmol/L respectively, p=0.002 by 
Wilcoxon rank-sum test). Overall, 44% of patients were deficient in 25-
hydroxyvitamin D with levels <50nmol/L, and 15% were severely deficient with 
levels <30nmol/L. Vitamin D levels tended to be lower among patients admitted 
earlier in the study (during July compared to October). 
 
25-hydroxyvitamin D levels were not correlated with either serum cathelicidin (rho=-
0.002, p=0.99) or beta defensin-2 (rho=-0.05, p=0.65). Nor were cathelicidin levels 
correlated with beta defensin-2 levels (rho=0.02, p=0.82).  
 
Patients with severe 25-hydroxyvitamin D deficiency (<30nmol/L) had higher 30 day 
mortality than patients with mildly deficient (30-49nmol/L) or sufficient (≥50nmol/L) 
25-hydroxyvitamin D levels (Figure 3). Forward and backward stepwise logistic 
regression models provided the same results. Of the potential covariates, only 
CURB65 scores were significantly associated with mortality and the association 
between low 25-hydroxyvitamin D and 30 day mortality persisted after adjusting for 
these (Table 2). Adjusting for the month of admission made no material difference to 
the results. 
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Crude 30-day mortality defined by categories of 25-hydroxyvitamin D, cathelicidin, 
CURB65 and beta defensin-2 are presented in Figure 3. Neither serum cathelicidin 
nor beta defensin-2 levels were significantly associated with 30 day mortality, 
although there was a trend to higher mortality in the lowest tertile of serum 
cathelicidin (p=0.08) (Figure 3) This lack of association remained after adjustment for 
covariates in the logistic regression models, in which CURB65 score was the only 
significant predictor of mortality (Table 3-4).  
 
Serum cathelicidin levels in 41 patients who provided blood samples at their clinical 
follow-up were not significantly different to those obtained on admission (median 
level on admission and follow-up = 83.1 ng/ml and 87.3 ng/ml respectively, p=0.52 
by paired t test). 
 
 
Discussion 
In this prospective cohort of patients admitted with community acquired pneumonia, 
severe 25-hydroxyvitamin D deficiency was associated with higher mortality within 
the first 30 days after admission. These associations were independent of patient age, 
sex, co-morbidities, the systemic inflammatory response, and other prognostic factors 
including CURB65 scores.  
 
The relationship between 25-hydroxyvitamin D concentrations and mortality was not 
linear. An increased risk of mortality was only apparent in those with severe 
deficiency (Figure 3). Further exploration of the data by categorising patients by 
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deciles of 25-hydroxyvitamin D levels confirmed that the threshold for increased 
mortality was around the 30nmol/L cut off for severe deficiency. To our knowledge 
this is the first prospective study to explore the association between 25-
hydroxyvitamin D, antimicrobial peptide levels and the severity or prognosis of 
community acquired pneumonia in an adult population. In children with acute lower 
respiratory tract infection, low 25-hydroxyvitamin D levels have been associated with 
admission to intensive care.21 In our cohort, 3 of the 4 patients who were admitted to 
intensive care had severe 25-hydroxyvitamin D deficiency (p=0.011 by Fisher’s exact 
test). 
 
We did not find any significant correlations between serum 25-hydroxyvitamin D, 
cathelicidin and beta defensin-2 levels. Hence our hypothesis that 25-hydroxyvitamin 
D would influence the outcome of community acquired pneumonia through 
differences in antimicrobial peptide levels was not supported. For cathelicidin, this 
may be because we measured the active peptide component LL-37 of cathelicidin and 
not the prepropeptide, which must be proteolytically cleaved to generate the mature 
active LL-37 peptide. There may also be many other factors that influence 
antimicrobial peptide concentrations. For example, the uptake of 25-hydroxyvitamin 
D into target cells and its subsequent 1-alpha-hydroxylation may influence 
antimicrobial peptide production to a greater extent than serum 25-hydroxyvitamin D 
levels.  In epithelial membranes and other extrarenal sites, 1-alpha hydroxylase 
activity is regulated locally by toll-like receptor activation, cytokines, growth factors 
and remains incompletely understood.22 Serum levels of immature or mature 
antimicrobial peptides may not correlate with airway concentrations, although 
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previous studies have shown positive correlations between plasma and 
bronchoalveolar lavage fluid defensin levels.14, 15 It is also possible that serum 1,25 
hydroxyvitamin D concentration is a stronger determinant of cathelicidin production 
than 25-hydroxyvitamin D, since it is the main active metabolite of vitamin D and has 
previously been shown to correlate with serum cathelicidin levels.23 However, 
measurement of 25-hydroxyvitamin D is regarded as the most accurate method of 
determining vitamin D status because it has a serum half-life of weeks compared to 
the half-life of 1,25-dihydroxyvitamin D, which is less than 4 hours. Moreover, 25-
hydroxyvitamin D deficiency results in a compensatory increase in parathyroid 
hormone secretion, which increases renal 1-alpha hydroxylase activity, maintaining 
1,25-dihydroxyvitamin D levels in the normal or even elevated range.11  
 
Lower values of serum cathelicidin showed a non-significant trend to an association 
with higher 30 day mortality. This appears to be consistent with research showing that 
cathelicidin supplementation is protective in murine models of sepsis.24 In addition, 
lower serum cathelicidin levels predict increased mortality due to infections over the 
following year in patients undergoing haemodialysis.23 An unexpected finding was 
that serum cathelicidin levels did not fall after recovery from the acute admission. 
This contrasts with previous studies of antimicrobial peptide levels in pneumonia, 
which showed trends to higher defensin levels during the acute phase of illness and a 
fall after completion of therapy, although these were small studies with sample sizes 
of less than 20.14, 15 In our cohort, there was a strong correlation between cathelicidin 
levels on admission and at follow up (Spearman’s rho = 0.59, p<0.001) and it seems 
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likely that cathelicidin levels are determined by factors other than acute respiratory 
infection. 
 
Serum beta defensin-2 did not predict 30 day mortality in this cohort. This may be 
because serum levels of beta defensin-2 may not reflect local concentrations, as it is 
mainly produced by epithelial leukocytes. In contrast, cathelicidin is produced by 
circulating neutrophils and myeloid cells in the bone marrow as well as epithelial 
cells. Therefore serum cathelicidin may be a better systemic marker of innate 
immunity than beta defensin-2.7  
 
As an observational study we cannot establish causal associations between 25-
hydroxyvitamin D deficiency and mortality in these patients. It is possible that these 
are simply serum markers of frailty and poor prognosis. Vitamin D deficiency may 
also reflect poor underlying nutritional status.25 However, few foods in nature are rich 
in vitamin D, and for most people, 90 percent of their vitamin D requirements are met 
by the conversion of cholesterol precursors in the skin to vitamin D3, by solar UV-B 
radiation.11 25-hydroxyvitamin D was not associated with the Charlson co-morbidity 
index or other indicators of frailty such as age or whether the patients lived in 
residential care. These covariates did not predict 30 day mortality in this study and do 
not explain the associations between low 25-hydroxyvitamin D levels and 30 day 
mortality.  
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A further limitation of this study is the relatively small sample size. This limits the 
complexity of the analyses and the extent to which we can adjust for multiple 
potential confounding factors at the same time. However, of the covariates tested, 
only CURB65 scores contributed to mortality and adjusting for this did not materially 
alter the associations between 25-hydroxyvitamin D deficiency and mortality. 
Adjusting for each of the other risk factors individually also made little difference to 
the findings: severe 25-hydroxyvitamin D deficiency remained a significant predictor 
of mortality. 
 
This was a hospital based cohort and although participation in the study was high, we 
cannot generalise these findings to patients treated in the community, nor can we 
determine the role that vitamin D may have on primary prevention of infection. 
Nevertheless, the findings support our hypothesis that 25-hydroxyvitamin D levels 
may influence the severity and outcomes of community acquired pneumonia, 
although we did not find the expected association between 25-hydroxyvitamin D and 
these peptides. There was also a trend towards increased 30 day mortality in patients 
with lower cathelicidin levels, although this did not reach statistical significance, 
possibly due to the small number of deaths. These observations raise the possibility 
that vitamin D supplements and cathelicidin could have a therapeutic role in acute 
infections. The role of vitamin D supplements in the primary prevention of these 
diseases also needs to be explored. In the meantime, 25-hydroxyvitamin D deficiency 
and serum cathelicidin levels may prove to be useful prognostic indicators in severe 
infections.   
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Table 1. Demographic and Baseline Clinical Characteristics 
Variable Community Acquired pneumonia 
n = 112 
Age - median yrs(range) 76 (16 – 97) 
Ethnicity   -- European 88 
                      Maori 22 
                      Other 2 
Current smoker  18 (17%) 
Ex Smoker 51 (48%) 
Never smoked 37 (35%) 
Charlson Comorbidity Index                  
Score 0-1 
 
57 (51%) 
Score 2-3 38 (34%) 
Score 4-7 17 (15%) 
CURB65 Score 0-1 32 (29%) 
CURB65 Score 2 32 (29%) 
CURB65 Score 3-5 48 (43%) 
Domicile Status  
        Living independently 59 (53%) 
        Requiring assistance 33 (30%) 
        Residential Care 19 (17%) 
25-hydroxyvitamin D median (range) nmol/L 54  (10, 140) 
Beta defensin-2 median (range) pg/mL 262 (14, 1734) 
Cathelicidin median (range) ng/mL 69 (13, 263) 
CRP median (range) mg/mL 170 (2, 550) 
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Table 2. Association between low serum 25-hydroxyvitamin D and 30 day mortality 
(n=112) 
 
 OR 95% CI P  
Severe 25-
hydroxyvitamin D 
deficiency 
13.5 2.6 to 69.1 0.002 
CURB65 score 2.23 1.13 to 4.40 0.021 
 
Analyses by stepwise logistic regression (entry method) using 30 day mortality as the 
dependant variable and 25-hydroxyvitamin D deficiency as the main predictor. Sex, age, 
CURB65 score, Charlson Index, CRP level, and living in residential care were entered into 
the model if they were significantly associated with mortality at p<0.05. Odds Ratios (OR) 
represent the odds of death in the 30 days following admission associated with low vitamin D 
status, and for each increment in the CURB65 score. 17 subjects had low vitamin D 
(<30nmol/L). Subjects with higher vitamin D values >30nmol/L are the reference category 
(n=95) 
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Table 3. Association between cathelicidin and 30 day mortality (n=103) 
 
 OR 95% CI P  
Cathelicidin 0.35 0.07 to 1.60 0.173 
CURB65 score 2.11 1.06 to 4.19 0.031 
 
Analyses by stepwise logistic regression (entry method) using 30 day mortality as the 
dependant variable and (log-)cathelicidin as the main predictor. Sex, age, admission 
diagnosis (COPD or pneumonia), CURB65 score, Charlson Index, CRP levels, and living in 
residential care were entered into the model if they were significantly associated with 
mortality at p<0.05. Odds Ratios (OR) represent the odds of mortality at 30 days associated 
with each log increment of cathelicidin levels and for each increment in the CURB65 score.  
 25 
 
Table 4. Association between beta defensin-2 and 30 day mortality (n=100) 
 OR 95% CI P  
Beta defensin-2 1.76 0.63 to 4.93 0.279 
CURB65 score 2.08 1.07 to 4.04 0.030 
 
Analyses by stepwise logistic regression (entry method) using 30 day mortality as the 
dependant variable and (log-)beta defensin-2 as the main predictor. Sex, age, admission 
diagnosis (COPD or pneumonia), CURB65 score, Charlson Index, CRP levels, and living in 
residential care were entered into the model if they were significantly associated with 
mortality at p<0.1. Odds Ratios (OR) represent the odds of mortality at 30 days associated 
with each log increment of beta defensin-2 levels and for each increment in the CURB65 
score.
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Figure Legends  
 
Figure 1 Patient enrolment and completion of study 
 
Figure 2 Scatter plot of serum 25-hydroxyvitamin D, cathelicidin and beta defensin 2 
levels. 
 
Figure 3 Unadjusted 30 day mortality by categories of 25-hydroxyvitamin D, 
cathelicidin, CURB-65 score and beta defensin-2. (Numbers above bars indicate deaths in 
each group. P values are for trend.) 
 
 



